Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Immunoassay Market: By Product Type, By Laboratory Throughput, By Laboratory Type, By Disease Indication, By End-user and Region Forecast 2020-2031
Immunoassay Market was valued at US$ 30,042 million in 2024 and is projected to reach US$ 42,272 million by 2031 at a CAGR of 5% from 2025-2031. The immunoassay market refers to a sector within the diagnostics and biotechnology industries that involves tests designed to detect and quantify substances such as hormones, proteins, and pathogens in biological samples. These tests use antibodies or antigens as a basis for detecting specific analytes. Immunoassays are commonly used in clinical diagnostics and drug testing. They offer high sensitivity, specificity, and speed, making them crucial tools in medical research, disease diagnosis, and therapeutic monitoring.
The market has witnessed significant growth in recent years, driven by advancements in technology and increasing demand for quick, accurate diagnostic tests. This market is primarily fuelled by the rise in chronic diseases, growing awareness of early detection, and the need for personalized medicine. Immunoassays are widely used in hospitals, laboratories, and research settings for applications such as cancer detection, cardiovascular disease monitoring, infectious disease diagnostics, and fertility testing. Additionally, the market is being shaped by the increasing adoption of point-of-care (POC) testing and the integration of automation in laboratory processes.
The global immunoassay market is highly competitive, with key players offering a broad range of products, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassay’s (RIA), and chemiluminescent immunoassays (CLIA). As the demand for faster and more accurate diagnostic tools grows, the market is expected to continue expanding, with growth in emerging regions and areas like oncology, immunology, and infectious diseases.
By Component: The Reagents and Kits segment is the leading driver in the immunoassay market. This segment is growing rapidly due to the critical role reagents and kits play in the effectiveness and reliability of immunoassay tests. Reagents, including antibodies and antigens, are essential for the detection and quantification of target molecules in biological samples. They are fundamental to the performance of various immunoassay techniques, such as enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), and radioimmunoassay’s (RIA). The increasing demand for these reagents and kits is primarily driven by the rising need for accurate and early diagnosis of chronic diseases such as cancer, diabetes, and cardiovascular disorders, which require frequent testing. Additionally, the growing prevalence of infectious diseases and the shift towards personalized medicine have further fuelled the demand for these products. Reagents and kits are widely used in clinical laboratories, hospitals, and research facilities, making them a cornerstone of the immunoassay market.
By Technology: Enzyme-Linked Immunosorbent Assay (ELISA) is the leading technology segment in the immunoassay market. ELISA has been the cornerstone of immunoassay testing due to its high sensitivity, versatility, and wide application across diagnostics, research, and monitoring. This technology involves using enzyme-linked antibodies to detect and quantify substances such as proteins, hormones, and pathogens in biological samples. ELISA's widespread use can be attributed to its ease of use, cost-effectiveness, and ability to handle a broad range of assays, including antigen and antibody detection.
The demand for ELISA-based tests is increasing, particularly in clinical diagnostics, where it is extensively used for disease detection, including HIV, cancer, and autoimmune disorders. Furthermore, the expansion of its applications into areas such as food safety testing, veterinary diagnostics, and environmental monitoring contributes significantly to the growth of the ELISA segment. The ability of ELISA to be adapted for high-throughput screening, coupled with advances in automation and miniaturization, is propelling its continued dominance in the market. With ongoing technological improvements aimed at enhancing assay sensitivity and reducing testing time, ELISA is expected to maintain its position as the leading technology in the immunoassay market, driving the growth of diagnostic testing worldwide.
By Test Type: Oncology is the leading test type segment in the immunoassay market. This segment has experienced significant growth due to the increasing global prevalence of cancer and the rising demand for early detection and monitoring tools. Immunoassays play a crucial role in oncology by detecting specific biomarkers related to various types of cancers, including prostate, breast, and colorectal cancers. Tests such as Free PSA (Prostate-Specific Antigen) and Total PSA are widely used for prostate cancer screening, while other cancer-related immunoassays are used for diagnostic purposes, assessing disease progression, and monitoring treatment efficacy. The demand for oncology immunoassays is driven by the increasing focus on personalized medicine, where targeted therapies are guided by the results of these biomarker-based tests.
In addition to the rise in cancer incidences, advancements in technology have improved the sensitivity and accuracy of oncology immunoassays, enabling the detection of biomarkers at earlier stages, which can significantly improve patient outcomes. This has further boosted the growth of the oncology segment in the immunoassay market. As healthcare systems around the world place greater emphasis on early diagnosis and preventative care, the oncology segment is expected to continue leading the market, with increasing investments in cancer research and diagnostic innovations.
By End-user: Private Hospitals lead the end-user segment in the immunoassay market. This segment is experiencing substantial growth due to the increasing demand for advanced diagnostic tools in private healthcare settings. Private hospitals often have access to cutting-edge technology and can invest in high-quality immunoassay systems, which are essential for the accurate and timely diagnosis of diseases such as cancer, cardiovascular conditions, and infectious diseases. The demand for immunoassays in private hospitals is driven by a higher volume of patients seeking specialized care, including personalized medicine, and the ability to perform a wide range of diagnostic tests in-house.
Moreover, private hospitals typically have faster turnaround times for test results, which enhances their ability to provide prompt treatment decisions, particularly for critically ill patients. The ability to offer a broad array of immunoassay-based diagnostic services also gives private hospitals a competitive edge, attracting more patients who seek timely and precise testing. This trend is further bolstered by the increasing focus on preventative healthcare and early disease detection, which private hospitals are well-positioned to support. As the demand for high-quality, rapid diagnostic solutions continues to rise, private hospitals are expected to maintain their dominant position in the immunoassay market, with continued investment in the latest testing technologies and expansion of services.
Study Period
2025-2031Base Year
2024CAGR
5.7%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The primary drivers of the immunoassay market are the increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and infectious diseases. As the global population ages and lifestyles become more sedentary, the incidence of these diseases has risen dramatically. This shift has created a higher demand for effective diagnostic tools, including immunoassays, that can offer rapid, accurate, and non-invasive detection methods. Early diagnosis plays a crucial role in improving treatment outcomes for many chronic diseases, and immunoassays are ideal for identifying biomarkers associated with these conditions. As healthcare systems around the world prioritize preventive care and early diagnosis, the market for immunoassays continues to grow, driven by the need for reliable, efficient testing solutions. This has led to the widespread use of immunoassays in routine clinical diagnostics, research, and disease monitoring, providing significant momentum to the market's expansion.
A significant restraint in the immunoassay market is the high cost associated with the development, production, and implementation of immunoassay systems. These tests often require specialized equipment, reagents, and qualified personnel to operate, which can lead to high operational costs. Furthermore, some immunoassay-based diagnostic tests can be expensive for patients and healthcare providers, especially in regions with limited healthcare budgets. While the benefits of immunoassays in terms of accuracy and speed are well recognized, the financial barriers associated with their widespread adoption in low-resource settings can limit their accessibility. Additionally, the costs of regulatory approvals and certifications for immunoassay products in different markets can add further financial strain on manufacturers. As a result, high costs remain a significant challenge for the market, especially in emerging economies, where cost-effectiveness is a crucial consideration for healthcare systems and end-users.
The immunoassay market is the continuous advancements in technology that are enhancing the performance and capabilities of immunoassay systems. Innovations such as the integration of artificial intelligence (AI), machine learning, and automation are improving the accuracy, speed, and efficiency of these diagnostic tools. AI, for example, can enhance data analysis in immunoassay results, allowing for more precise and faster interpretations, especially in complex cases. Automation is streamlining workflows in laboratories, reducing human error, and increasing throughput. Additionally, new developments in multiplex immunoassays, which allow the simultaneous detection of multiple analytes from a single sample, are driving the evolution of immunoassay systems. These technologies not only improve the efficiency of diagnostic testing but also reduce operational costs and time, making immunoassays more accessible to a broader range of healthcare settings. As these technological advancements continue to emerge, they offer significant growth opportunities for the market, particularly in clinical diagnostics, personalized medicine, and research applications.
The immunoassay market is the growing adoption of point-of-care testing (POCT) solutions. Point-of-care testing allows healthcare providers to conduct diagnostic tests at or near the patient’s location, reducing the time it takes to get results and facilitating quicker treatment decisions. Immunoassays, with their high specificity and sensitivity, are well-suited for POCT applications, particularly in emergency care, primary healthcare settings, and remote areas where laboratory infrastructure may be lacking. This trend is further bolstered by the rising demand for home-based diagnostics and self-testing kits, providing consumers with the convenience of performing tests at home. Innovations in immunoassay technologies, such as the development of portable, user-friendly devices, are making POCT more accessible and efficient. This trend is not only transforming healthcare delivery but also significantly expanding the market for immunoassay-based tests, as they become an integral part of modern diagnostic practices.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 30,042 million |
Market Size in 2031 |
US$ 42,272 million |
Market CAGR |
5.7% |
By Product Type |
|
By Laboratory Throughput |
|
By Laboratory Type |
|
By Disease Indication |
|
By End User |
|
By Region |
|
Download Free Sample Report
The global immunoassay market size was valued at US$ 30,042 million in 2024 and is projected to reach US$ 42,272 million by 2031 at a CAGR of 5% from 2025-2031.
Bio-Rad Laboratories Inc., Thermo Fisher Scientific , EMD Millipore (Merck KGaA., Becton, Dickinson and Company., Microsynth AG, Quansys Biosciences Inc , QIAGEN N.V., Hoffmann-La Roche Ltd.
Asia-Pacific is dominating the immunoassay market
1. Executive Summary |
2. Global Immunoassay Market Introduction |
2.1. Global Immunoassay Market - Taxonomy |
2.2. Global Immunoassay Market - Definitions |
2.2.1. By Product Type |
2.2.2. By Laboratory Throughput |
2.2.3. By Laboratory Type |
2.2.4. By Disease Indication |
2.2.5. By End-user |
2.2.6. By Region |
3. Global Immunoassay Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Key Developments |
4. Global Immunoassay Market By Product Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
4.1. Reagents and Kits |
4.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3. Market Opportunity Analysis |
4.2. Instruments |
4.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3. Market Opportunity Analysis |
4.3. Services |
4.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
5. Global Immunoassay Market By Laboratory Throughput, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
5.1. Small |
5 1 1 Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Mid |
5.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. High |
5.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Ultra High Applicable |
5.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Immunoassay Market By Laboratory Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
6.1. Public |
6.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Private |
6.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Immunoassay Market By Disease Indication, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
7.1. Thyroid |
7.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Cardiac |
7.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Reproductive and Fertility |
7.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Infectious Diseases |
7.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Tumor Markers |
7.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Bone Health |
7.6.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Diabetes |
7.7.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
7.8. Sepsis |
7.8.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.8.3. Market Opportunity Analysis |
7.9. Neurology |
7.9.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.9.3. Market Opportunity Analysis |
7.10. Others |
7.10.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
7.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.10.3. Market Opportunity Analysis |
8. Global Immunoassay Market, By End-user, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
8.1. Hospital Labs/University Labs |
8.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Diagnostic Labs |
8.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
9. Global Immunoassay Market By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific |
9.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. MEA |
9.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Immunoassay Market - Opportunity Analysis Index, By Laboratory Throughput, Product Type, Laboratory Type, Disease Indication, End-user, , , and Region, 2025-2031 |
10. North America Immunoassay Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
10.1. Product Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Reagents and Kits |
10.1.2. Instruments |
10.1.3. Services |
10.2. Laboratory Throughput Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Small |
10.2.2. Mid |
10.2.3. High |
10.2.4. Ultra High Applicable |
10.3. Laboratory Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Public |
10.3.2. Private |
10.4. Disease Indication Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Thyroid |
10.4.2. Cardiac |
10.4.3. Reproductive and Fertility |
10.4.4. Infectious Diseases |
10.4.5. Tumor Markers |
10.4.6. Bone Health |
10.4.6. Diabetes |
10.4.7. Sepsis |
10.4.8. Neurology |
10.4.9. Others |
10.5. End-user Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1. Hospital Labs/University Labs |
10.5.2. Diagnostic Labs |
10.6. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.6.1. USA |
10.6.2. Canada |
11. Europe Immunoassay Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
11.1. Product Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Reagents and Kits |
11.1.2. Instruments |
11.1.3. Services |
11.2. Laboratory Throughput Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Small |
11.2.2. Mid |
11.2.3. High |
11.2.4. Ultra High Applicable |
11.3. Laboratory Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Public |
11.3.2. Private |
11.4. Disease Indication Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Thyroid |
11.4.2. Cardiac |
11.4.3. Reproductive and Fertility |
11.4.4. Infectious Diseases |
11.4.5. Tumor Markers |
11.4.6. Bone Health |
11.4.7. Diabetes |
11.4.8. Sepsis |
11.4.9. Neurology |
11.4.10. Others |
11.5. End-user Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1. Hospital Labs/University Labs |
11.5.2. Diagnostic Labs |
11.6. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.6.1. Germany |
11.6.2. UK |
11.6.3. France |
11.6.4. Italy |
11.6.5. Spain |
11.6.6. Rest of Europe |
12. Asia Pacific Immunoassay Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
12.1. Product Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Reagents and Kits |
12.1.2. Instruments |
12.1.3. Services |
12.2. Laboratory Throughput Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Small |
12.2.2. Mid |
12.2.3. High |
12.2.4. Ultra High Applicable |
12.3. Laboratory Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Public |
12.3.2. Private |
12.4. Disease Indication Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Thyroid |
12.4.2. Cardiac |
12.4.3. Reproductive and Fertility |
12.4.4. Infectious Diseases |
12.4.5. Tumor Markers |
12.4.6. Bone Health |
12.4.7. Diabetes |
12.4.8. Sepsis |
12.4.9. Neurology |
12.4.10. Others |
12.5. End-user Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1. Hospital Labs/University Labs |
12.5.2. Diagnostic Labs |
12.6. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.6.1. China |
12.6.2. India |
12.6.3. Japan |
12.6.4. South Korea |
12.6.5. ASEAN Countries |
12.6.6. Rest of APAC |
13. Latin America Immunoassay Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
13.1. Product Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Reagents and Kits |
13.1.2. Instruments |
13.1.3. Services |
13.2. Laboratory Throughput Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Small |
13.2.2. Mid |
13.2.3. High |
13.2.4. Ultra High Applicable |
13.3. Laboratory Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Public |
13.3.2. Private |
13.4. Disease Indication Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Thyroid |
13.4.2. Cardiac |
13.4.3. Reproductive and Fertility |
13.4.4. Infectious Diseases |
13.4.5. Tumor Markers |
13.4.6. Bone Health |
13.4.7. Diabetes |
13.4.8. Sepsis |
13.4.9. Neurology |
13.4.10. Others |
13.5. End-user Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1. Hospital Labs/University Labs |
13.5.2. Diagnostic Labs |
13.6. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.6.1. Brazil |
13.6.2. Mexico |
13.6.3. Argentina |
13.6.4. Rest of Latin America |
14. MEA Immunoassay Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
14.1. Product Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Reagents and Kits |
14.1.2. Instruments |
14.1.3. Services |
14.2. Laboratory Throughput Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Small |
14.2.2. Mid |
14.2.3. High |
14.2.4. Ultra High Applicable |
14.3. Laboratory Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1. Public |
14.3.2. Private |
14.4. Disease Indication Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1. Thyroid |
14.4.2. Cardiac |
14.4.3. Reproductive and Fertility |
14.4.4. Infectious Diseases |
14.4.5. Tumor Markers |
14.4.6. Bone Health |
14.4.7. Diabetes |
14.4.8. Sepsis |
14.4.9. Neurology |
14.4.10. Others |
14.5. End-user Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1. Hospital Labs/University Labs |
14.5.2. Diagnostic Labs |
14.6. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.6.1. GCC Countries |
14.6.2. Israel |
14.6.3. South Africa |
14.6.4. Rest of MEA |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Abbott |
15.2.2. Siemens Healthineers |
15.2.3. Beckman Coulter |
15.2.4. bioMérieux SA |
15.2.5. QuidelOrtho |
15.2.6. Sysmex Corporation |
15.2.7. Bio-Rad Laboratories, Inc. |
15.2.8. Hoffmann-La Roche AG |
15.2.9. Becton, Dickinson, and Company |
15.2.10. Thermo Fisher Scientific, Inc. |
15.2.11. DiaSorin S.p.A. |
15.2.12. Mindray |
15.2.13. SNIBE |
16. Research Methodology |
17. Key Assumptions and Acronyms |
Key Market Players